| A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement M Eslam, PN Newsome, SK Sarin, QM Anstee, G Targher, ... Journal of hepatology 73 (1), 202-209, 2020 | 3677 | 2020 |
| Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis E Vilar-Gomez, Y Martinez-Perez, L Calzadilla-Bertot, A Torres-Gonzalez, ... Gastroenterology 149 (2), 367-378. e5, 2015 | 2325 | 2015 |
| Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection N Afdhal, S Zeuzem, P Kwo, M Chojkier, N Gitlin, M Puoti, ... New England Journal of Medicine 370 (20), 1889-1898, 2014 | 2174 | 2014 |
| Genomewide Association Study of Severe Covid-19 with Respiratory Failure D Ellinghaus, F Degenhardt, L Bujanda, M Buti, A Albillos, P Invernizzi, ... New England Journal of Medicine, 2020 | 1997* | 2020 |
| Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030 C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ... Journal of hepatology 69 (4), 896-904, 2018 | 1786 | 2018 |
| Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period.(vol 129, pg 512, 2005) RJ Andrade, MI Lucena, MC Fernandez, G Pelaez, K Pachkoria, ... Gastroenterology 129 (5), 1808-1808, 2005 | 1393* | 2005 |
| Treatment of NAFLD with diet, physical activity and exercise M Romero-Gómez, S Zelber-Sagi, M Trenell Journal of hepatology 67 (4), 829-846, 2017 | 1330 | 2017 |
| Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial ZM Younossi, V Ratziu, R Loomba, M Rinella, QM Anstee, Z Goodman, ... The Lancet 394 (10215), 2184-2196, 2019 | 1170 | 2019 |
| Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ... Gastroenterology 150 (5), 1147-1159. e5, 2016 | 1167 | 2016 |
| Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients M Romero-Gómez, MDM Viloria, RJ Andrade, J Salmerón, M Diago, ... Gastroenterology 128 (3), 636-641, 2005 | 935 | 2005 |
| Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis S McPherson, T Hardy, JF Dufour, S Petta, M Romero-Gomez, M Allison, ... The American journal of gastroenterology 112 (5), 740, 2017 | 761 | 2017 |
| Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates Z Younossi, M Stepanova, JP Ong, IM Jacobson, E Bugianesi, A Duseja, ... Clinical Gastroenterology and Hepatology 17 (4), 748-755. e3, 2019 | 734 | 2019 |
| Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study E Vilar-Gomez, L Calzadilla-Bertot, VWS Wong, M Castellanos, ... Gastroenterology 155 (2), 443-457. e17, 2018 | 727 | 2018 |
| Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy M Romero-Gómez, F Boza, MS Garcı́a-Valdecasas, E Garcı́a, ... The American journal of gastroenterology 96 (9), 2718-2723, 2001 | 573 | 2001 |
| Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles MI Lucena, M Molokhia, Y Shen, TJ Urban, GP Aithal, RJ Andrade, ... Gastroenterology 141 (1), 338-347, 2011 | 516 | 2011 |
| Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment JM Sánchez–Tapias, M Diago, P Escartín, J Enríquez, M Romero–Gómez, ... Gastroenterology 131 (2), 451-460, 2006 | 478 | 2006 |
| Phenotypic characterization of idiosyncratic drug‐induced liver injury: the influence of age and sex MI Lucena, RJ Andrade, N Kaplowitz, M García‐Cortes, MC Fernández, ... Hepatology 49 (6), 2001-2009, 2009 | 434 | 2009 |
| Value of the critical flicker frequency in patients with minimal hepatic encephalopathy M Romero‐Gómez, J Córdoba, R Jover, JA Del Olmo, M Ramírez, R Rey, ... Hepatology 45 (4), 879-885, 2007 | 427 | 2007 |
| Outcome of acute idiosyncratic drug‐induced liver injury: long‐term follow‐up in a hepatotoxicity registry RJ Andrade, MI Lucena, N Kaplowitz, B García‐Muņoz, Y Borraz, ... Hepatology 44 (6), 1581-1588, 2006 | 412 | 2006 |
| Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials SA Harrison, VWS Wong, T Okanoue, N Bzowej, R Vuppalanchi, ... Journal of hepatology 73 (1), 26-39, 2020 | 388 | 2020 |
Javier AmpueroHospital Universitario Virgen del Rocío. Instituto de Biomedicina de Sevilla. Universidad de SevillaVerified email at us.es
